nodes	percent_of_prediction	percent_of_DWPC	metapath
Nateglinide—Bortezomib—hematologic cancer	0.434	1	CrCtD
Nateglinide—Aspartame—Bortezomib—hematologic cancer	0.067	0.33	CrCrCtD
Nateglinide—Lacosamide—Bortezomib—hematologic cancer	0.067	0.33	CrCrCtD
Nateglinide—Phenacemide—Vorinostat—hematologic cancer	0.0534	0.263	CrCrCtD
Nateglinide—ALB—hematologic cancer	0.0255	1	CbGaD
Nateglinide—ABCC4—Tioguanine—hematologic cancer	0.0246	0.108	CbGbCtD
Nateglinide—L-Phenylalanine—Melphalan—hematologic cancer	0.0157	0.0773	CrCrCtD
Nateglinide—ABCC4—Mercaptopurine—hematologic cancer	0.0102	0.0447	CbGbCtD
Nateglinide—ORM1—Imatinib—hematologic cancer	0.00889	0.0389	CbGbCtD
Nateglinide—UGT1A9—Irinotecan—hematologic cancer	0.00753	0.033	CbGbCtD
Nateglinide—SLC16A1—Methotrexate—hematologic cancer	0.00694	0.0304	CbGbCtD
Nateglinide—PTGS1—Bortezomib—hematologic cancer	0.00684	0.03	CbGbCtD
Nateglinide—PTGS1—Thalidomide—hematologic cancer	0.00596	0.0261	CbGbCtD
Nateglinide—PTGS1—Ifosfamide—hematologic cancer	0.00524	0.023	CbGbCtD
Nateglinide—PTGS1—Imatinib—hematologic cancer	0.00501	0.0219	CbGbCtD
Nateglinide—CYP2C9—Bexarotene—hematologic cancer	0.00449	0.0197	CbGbCtD
Nateglinide—CYP3A7—Ifosfamide—hematologic cancer	0.0042	0.0184	CbGbCtD
Nateglinide—CYP3A7-CYP3A51P—Ifosfamide—hematologic cancer	0.0042	0.0184	CbGbCtD
Nateglinide—CYP3A7—Imatinib—hematologic cancer	0.00401	0.0176	CbGbCtD
Nateglinide—CYP3A7-CYP3A51P—Imatinib—hematologic cancer	0.00401	0.0176	CbGbCtD
Nateglinide—CYP3A5—Daunorubicin—hematologic cancer	0.00392	0.0172	CbGbCtD
Nateglinide—CYP2D6—Lomustine—hematologic cancer	0.00382	0.0167	CbGbCtD
Nateglinide—ALB—Imatinib—hematologic cancer	0.00374	0.0164	CbGbCtD
Nateglinide—CYP2C9—Idarubicin—hematologic cancer	0.00372	0.0163	CbGbCtD
Nateglinide—CYP3A5—Thalidomide—hematologic cancer	0.00357	0.0157	CbGbCtD
Nateglinide—CYP3A5—Teniposide—hematologic cancer	0.00341	0.0149	CbGbCtD
Nateglinide—CYP2D6—Idarubicin—hematologic cancer	0.0034	0.0149	CbGbCtD
Nateglinide—ABCC4—Methotrexate—hematologic cancer	0.00334	0.0146	CbGbCtD
Nateglinide—CYP3A5—Ifosfamide—hematologic cancer	0.00315	0.0138	CbGbCtD
Nateglinide—CYP3A5—Imatinib—hematologic cancer	0.00301	0.0132	CbGbCtD
Nateglinide—CYP2D6—Hydroxyurea—hematologic cancer	0.00289	0.0127	CbGbCtD
Nateglinide—CYP2C9—Bortezomib—hematologic cancer	0.00275	0.0121	CbGbCtD
Nateglinide—CYP3A4—Bexarotene—hematologic cancer	0.00261	0.0114	CbGbCtD
Nateglinide—CYP2D6—Bortezomib—hematologic cancer	0.00252	0.011	CbGbCtD
Nateglinide—PTGS1—Etoposide—hematologic cancer	0.00251	0.011	CbGbCtD
Nateglinide—CYP3A7-CYP3A51P—Irinotecan—hematologic cancer	0.0025	0.011	CbGbCtD
Nateglinide—CYP3A7—Irinotecan—hematologic cancer	0.0025	0.011	CbGbCtD
Nateglinide—ALB—Prednisone—hematologic cancer	0.00246	0.0108	CbGbCtD
Nateglinide—CYP3A4—Busulfan—hematologic cancer	0.00243	0.0106	CbGbCtD
Nateglinide—CYP3A4—Lomustine—hematologic cancer	0.00243	0.0106	CbGbCtD
Nateglinide—CYP3A5—Dasatinib—hematologic cancer	0.00241	0.0106	CbGbCtD
Nateglinide—CYP2C9—Thalidomide—hematologic cancer	0.0024	0.0105	CbGbCtD
Nateglinide—ALB—Irinotecan—hematologic cancer	0.00234	0.0102	CbGbCtD
Nateglinide—CYP2C9—Teniposide—hematologic cancer	0.00229	0.01	CbGbCtD
Nateglinide—CYP3A7-CYP3A51P—Vincristine—hematologic cancer	0.00219	0.00959	CbGbCtD
Nateglinide—CYP3A7—Vincristine—hematologic cancer	0.00219	0.00959	CbGbCtD
Nateglinide—CYP3A4—Thiotepa—hematologic cancer	0.00216	0.00948	CbGbCtD
Nateglinide—CYP2C9—Ifosfamide—hematologic cancer	0.00211	0.00925	CbGbCtD
Nateglinide—CYP2C9—Imatinib—hematologic cancer	0.00202	0.00883	CbGbCtD
Nateglinide—CYP3A5—Irinotecan—hematologic cancer	0.00188	0.00823	CbGbCtD
Nateglinide—CYP2D6—Imatinib—hematologic cancer	0.00184	0.00808	CbGbCtD
Nateglinide—CYP2C9—Nilotinib—hematologic cancer	0.00183	0.00803	CbGbCtD
Nateglinide—CYP3A4—Methoxsalen—hematologic cancer	0.00168	0.00737	CbGbCtD
Nateglinide—CYP2D6—Nilotinib—hematologic cancer	0.00168	0.00734	CbGbCtD
Nateglinide—CYP2D6—Vinorelbine—hematologic cancer	0.00166	0.00728	CbGbCtD
Nateglinide—CYP3A7-CYP3A51P—Dexamethasone—hematologic cancer	0.00165	0.00722	CbGbCtD
Nateglinide—CYP3A7—Dexamethasone—hematologic cancer	0.00165	0.00722	CbGbCtD
Nateglinide—CYP3A5—Vincristine—hematologic cancer	0.00164	0.00719	CbGbCtD
Nateglinide—CYP3A4—Bortezomib—hematologic cancer	0.0016	0.00701	CbGbCtD
Nateglinide—CYP3A4—Daunorubicin—hematologic cancer	0.00153	0.0067	CbGbCtD
Nateglinide—CYP3A5—Etoposide—hematologic cancer	0.0015	0.00659	CbGbCtD
Nateglinide—SLC22A6—Methotrexate—hematologic cancer	0.00145	0.00636	CbGbCtD
Nateglinide—CYP3A4—Cytarabine—hematologic cancer	0.00135	0.00591	CbGbCtD
Nateglinide—CYP3A4—Teniposide—hematologic cancer	0.00133	0.00583	CbGbCtD
Nateglinide—CYP3A5—Dexamethasone—hematologic cancer	0.00124	0.00542	CbGbCtD
Nateglinide—ALB—Methotrexate—hematologic cancer	0.00124	0.00542	CbGbCtD
Nateglinide—CYP3A4—Ifosfamide—hematologic cancer	0.00123	0.00538	CbGbCtD
Nateglinide—CYP3A4—Imatinib—hematologic cancer	0.00117	0.00514	CbGbCtD
Nateglinide—CYP3A4—Ruxolitinib—hematologic cancer	0.0011	0.00484	CbGbCtD
Nateglinide—CYP3A4—Nilotinib—hematologic cancer	0.00107	0.00467	CbGbCtD
Nateglinide—CYP3A4—Vinorelbine—hematologic cancer	0.00106	0.00463	CbGbCtD
Nateglinide—CYP2C9—Cisplatin—hematologic cancer	0.00103	0.0045	CbGbCtD
Nateglinide—CYP2D6—Vinblastine—hematologic cancer	0.00102	0.00449	CbGbCtD
Nateglinide—CYP3A4—Triamcinolone—hematologic cancer	0.000966	0.00423	CbGbCtD
Nateglinide—CYP3A4—Dasatinib—hematologic cancer	0.000942	0.00412	CbGbCtD
Nateglinide—CYP3A4—Mitoxantrone—hematologic cancer	0.00093	0.00407	CbGbCtD
Nateglinide—CYP2C9—Dexamethasone—hematologic cancer	0.000829	0.00363	CbGbCtD
Nateglinide—CYP3A4—Betamethasone—hematologic cancer	0.000829	0.00363	CbGbCtD
Nateglinide—CYP3A4—Prednisolone—hematologic cancer	0.000818	0.00358	CbGbCtD
Nateglinide—CYP3A4—Prednisone—hematologic cancer	0.000772	0.00338	CbGbCtD
Nateglinide—CYP2D6—Dexamethasone—hematologic cancer	0.000758	0.00332	CbGbCtD
Nateglinide—CYP3A4—Irinotecan—hematologic cancer	0.000732	0.00321	CbGbCtD
Nateglinide—CYP3A4—Vinblastine—hematologic cancer	0.000651	0.00285	CbGbCtD
Nateglinide—CYP3A4—Vincristine—hematologic cancer	0.00064	0.0028	CbGbCtD
Nateglinide—CYP2D6—Doxorubicin—hematologic cancer	0.000629	0.00276	CbGbCtD
Nateglinide—CYP3A4—Etoposide—hematologic cancer	0.000586	0.00257	CbGbCtD
Nateglinide—KCNJ11—hematopoietic system—hematologic cancer	0.000493	0.0552	CbGeAlD
Nateglinide—CYP3A4—Dexamethasone—hematologic cancer	0.000482	0.00211	CbGbCtD
Nateglinide—SLC16A1—hematopoietic system—hematologic cancer	0.000413	0.0463	CbGeAlD
Nateglinide—CYP3A4—Doxorubicin—hematologic cancer	0.0004	0.00175	CbGbCtD
Nateglinide—ORM1—hematopoietic system—hematologic cancer	0.000371	0.0415	CbGeAlD
Nateglinide—PPARG—Ponatinib—Nilotinib—hematologic cancer	0.000357	0.285	CbGdCrCtD
Nateglinide—PPARG—hematopoietic system—hematologic cancer	0.000347	0.0388	CbGeAlD
Nateglinide—ABCC4—hematopoietic system—hematologic cancer	0.000315	0.0352	CbGeAlD
Nateglinide—SLC16A1—gonad—hematologic cancer	0.000314	0.0352	CbGeAlD
Nateglinide—PPARG—Ponatinib—Imatinib—hematologic cancer	0.00027	0.216	CbGdCrCtD
Nateglinide—PPARG—Topotecan—Irinotecan—hematologic cancer	0.000256	0.204	CbGdCrCtD
Nateglinide—PPARG—Etoposide—Teniposide—hematologic cancer	0.000255	0.203	CbGdCrCtD
Nateglinide—ABCC8—testis—hematologic cancer	0.000249	0.0279	CbGeAlD
Nateglinide—ORM1—blood—hematologic cancer	0.000246	0.0275	CbGeAlD
Nateglinide—SLC16A1—lung—hematologic cancer	0.00024	0.0269	CbGeAlD
Nateglinide—ORM1—bone marrow—hematologic cancer	0.000238	0.0266	CbGeAlD
Nateglinide—PPARG—blood—hematologic cancer	0.00023	0.0257	CbGeAlD
Nateglinide—SLC16A1—testis—hematologic cancer	0.000226	0.0253	CbGeAlD
Nateglinide—PPARG—bone marrow—hematologic cancer	0.000222	0.0249	CbGeAlD
Nateglinide—ORM1—lung—hematologic cancer	0.000215	0.0241	CbGeAlD
Nateglinide—ABCC4—blood—hematologic cancer	0.000209	0.0233	CbGeAlD
Nateglinide—CYP3A5—hematopoietic system—hematologic cancer	0.000206	0.0231	CbGeAlD
Nateglinide—CYP2C9—hematopoietic system—hematologic cancer	0.000203	0.0227	CbGeAlD
Nateglinide—ABCC4—bone marrow—hematologic cancer	0.000202	0.0226	CbGeAlD
Nateglinide—PPARG—lung—hematologic cancer	0.000201	0.0225	CbGeAlD
Nateglinide—KCNJ11—lymph node—hematologic cancer	0.000196	0.0219	CbGeAlD
Nateglinide—PPARG—testis—hematologic cancer	0.00019	0.0213	CbGeAlD
Nateglinide—PTGS1—hematopoietic system—hematologic cancer	0.000185	0.0207	CbGeAlD
Nateglinide—ABCC4—lung—hematologic cancer	0.000183	0.0205	CbGeAlD
Nateglinide—SLC15A2—blood—hematologic cancer	0.00018	0.0201	CbGeAlD
Nateglinide—ALB—testis—hematologic cancer	0.000178	0.02	CbGeAlD
Nateglinide—ABCC4—testis—hematologic cancer	0.000173	0.0193	CbGeAlD
Nateglinide—SLC16A1—lymph node—hematologic cancer	0.000164	0.0184	CbGeAlD
Nateglinide—SLC15A2—lung—hematologic cancer	0.000158	0.0176	CbGeAlD
Nateglinide—CYP3A4—hematopoietic system—hematologic cancer	0.000155	0.0173	CbGeAlD
Nateglinide—CYP2D6—hematopoietic system—hematologic cancer	0.000152	0.0171	CbGeAlD
Nateglinide—SLC15A2—testis—hematologic cancer	0.000149	0.0167	CbGeAlD
Nateglinide—ORM1—lymph node—hematologic cancer	0.000147	0.0165	CbGeAlD
Nateglinide—PPARG—lymph node—hematologic cancer	0.000138	0.0154	CbGeAlD
Nateglinide—CYP3A5—blood—hematologic cancer	0.000137	0.0153	CbGeAlD
Nateglinide—CYP2C9—blood—hematologic cancer	0.000135	0.0151	CbGeAlD
Nateglinide—ALB—lymph node—hematologic cancer	0.000129	0.0145	CbGeAlD
Nateglinide—ABCC4—lymph node—hematologic cancer	0.000125	0.014	CbGeAlD
Nateglinide—PTGS1—blood—hematologic cancer	0.000123	0.0137	CbGeAlD
Nateglinide—CYP3A5—lung—hematologic cancer	0.00012	0.0134	CbGeAlD
Nateglinide—PPARG—Teniposide—Etoposide—hematologic cancer	0.000115	0.0921	CbGdCrCtD
Nateglinide—SLC15A2—lymph node—hematologic cancer	0.000108	0.0121	CbGeAlD
Nateglinide—PTGS1—lung—hematologic cancer	0.000108	0.0121	CbGeAlD
Nateglinide—CYP3A4—blood—hematologic cancer	0.000103	0.0115	CbGeAlD
Nateglinide—PTGS1—testis—hematologic cancer	0.000102	0.0114	CbGeAlD
Nateglinide—CYP2D6—blood—hematologic cancer	0.000101	0.0113	CbGeAlD
Nateglinide—CYP2D6—testis—hematologic cancer	8.35e-05	0.00935	CbGeAlD
Nateglinide—PTGS1—lymph node—hematologic cancer	7.36e-05	0.00824	CbGeAlD
Nateglinide—Lacosamide—CA9—hematologic cancer	6.28e-05	0.475	CrCbGaD
Nateglinide—Abdominal pain—Mitoxantrone—hematologic cancer	3.24e-05	0.000511	CcSEcCtD
Nateglinide—Abdominal pain—Irinotecan—hematologic cancer	3.24e-05	0.000511	CcSEcCtD
Nateglinide—Nausea—Hydroxyurea—hematologic cancer	3.24e-05	0.00051	CcSEcCtD
Nateglinide—Vomiting—Bortezomib—hematologic cancer	3.23e-05	0.00051	CcSEcCtD
Nateglinide—Bronchitis—Epirubicin—hematologic cancer	3.23e-05	0.000509	CcSEcCtD
Nateglinide—Hypersensitivity—Alitretinoin—hematologic cancer	3.22e-05	0.000507	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Cisplatin—hematologic cancer	3.21e-05	0.000506	CcSEcCtD
Nateglinide—Vomiting—Bleomycin—hematologic cancer	3.21e-05	0.000506	CcSEcCtD
Nateglinide—Rash—Bortezomib—hematologic cancer	3.21e-05	0.000506	CcSEcCtD
Nateglinide—Dermatitis—Bortezomib—hematologic cancer	3.2e-05	0.000505	CcSEcCtD
Nateglinide—Rash—Bleomycin—hematologic cancer	3.18e-05	0.000502	CcSEcCtD
Nateglinide—Dermatitis—Bleomycin—hematologic cancer	3.18e-05	0.000501	CcSEcCtD
Nateglinide—Hypersensitivity—Ifosfamide—hematologic cancer	3.18e-05	0.000501	CcSEcCtD
Nateglinide—Asthenia—Carmustine—hematologic cancer	3.16e-05	0.000498	CcSEcCtD
Nateglinide—Vomiting—Vinorelbine—hematologic cancer	3.16e-05	0.000498	CcSEcCtD
Nateglinide—Diarrhoea—Thalidomide—hematologic cancer	3.14e-05	0.000495	CcSEcCtD
Nateglinide—Dizziness—Thiotepa—hematologic cancer	3.14e-05	0.000495	CcSEcCtD
Nateglinide—Asthenia—Alitretinoin—hematologic cancer	3.13e-05	0.000494	CcSEcCtD
Nateglinide—Rash—Vinorelbine—hematologic cancer	3.13e-05	0.000494	CcSEcCtD
Nateglinide—Dermatitis—Vinorelbine—hematologic cancer	3.13e-05	0.000493	CcSEcCtD
Nateglinide—Upper respiratory tract infection—Epirubicin—hematologic cancer	3.12e-05	0.000492	CcSEcCtD
Nateglinide—Influenza—Doxorubicin—hematologic cancer	3.11e-05	0.00049	CcSEcCtD
Nateglinide—Immune system disorder—Prednisone—hematologic cancer	3.1e-05	0.000489	CcSEcCtD
Nateglinide—Hypersensitivity—Vincristine—hematologic cancer	3.1e-05	0.000489	CcSEcCtD
Nateglinide—Asthenia—Ifosfamide—hematologic cancer	3.09e-05	0.000488	CcSEcCtD
Nateglinide—Pruritus—Alitretinoin—hematologic cancer	3.09e-05	0.000487	CcSEcCtD
Nateglinide—Sweating—Methotrexate—hematologic cancer	3.07e-05	0.000484	CcSEcCtD
Nateglinide—Pruritus—Ifosfamide—hematologic cancer	3.05e-05	0.000481	CcSEcCtD
Nateglinide—Dizziness—Thalidomide—hematologic cancer	3.03e-05	0.000478	CcSEcCtD
Nateglinide—Hepatobiliary disease—Methotrexate—hematologic cancer	3.03e-05	0.000477	CcSEcCtD
Nateglinide—Nausea—Bortezomib—hematologic cancer	3.02e-05	0.000476	CcSEcCtD
Nateglinide—Hypersensitivity—Mitoxantrone—hematologic cancer	3.02e-05	0.000476	CcSEcCtD
Nateglinide—Hypersensitivity—Irinotecan—hematologic cancer	3.02e-05	0.000476	CcSEcCtD
Nateglinide—Asthenia—Vincristine—hematologic cancer	3.02e-05	0.000476	CcSEcCtD
Nateglinide—Vomiting—Thiotepa—hematologic cancer	3.02e-05	0.000475	CcSEcCtD
Nateglinide—Diarrhoea—Carmustine—hematologic cancer	3.01e-05	0.000475	CcSEcCtD
Nateglinide—Nausea—Bleomycin—hematologic cancer	3e-05	0.000473	CcSEcCtD
Nateglinide—Malnutrition—Prednisone—hematologic cancer	2.99e-05	0.000472	CcSEcCtD
Nateglinide—Rash—Thiotepa—hematologic cancer	2.99e-05	0.000472	CcSEcCtD
Nateglinide—Bronchitis—Doxorubicin—hematologic cancer	2.99e-05	0.000471	CcSEcCtD
Nateglinide—Dermatitis—Thiotepa—hematologic cancer	2.99e-05	0.000471	CcSEcCtD
Nateglinide—Hyperhidrosis—Triamcinolone—hematologic cancer	2.99e-05	0.000471	CcSEcCtD
Nateglinide—Diarrhoea—Alitretinoin—hematologic cancer	2.99e-05	0.000471	CcSEcCtD
Nateglinide—Diarrhoea—Ifosfamide—hematologic cancer	2.95e-05	0.000465	CcSEcCtD
Nateglinide—Nausea—Vinorelbine—hematologic cancer	2.95e-05	0.000465	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Etoposide—hematologic cancer	2.94e-05	0.000464	CcSEcCtD
Nateglinide—Asthenia—Irinotecan—hematologic cancer	2.94e-05	0.000463	CcSEcCtD
Nateglinide—Asthenia—Mitoxantrone—hematologic cancer	2.94e-05	0.000463	CcSEcCtD
Nateglinide—Fatigue—Etoposide—hematologic cancer	2.94e-05	0.000463	CcSEcCtD
Nateglinide—Neuropathy peripheral—Epirubicin—hematologic cancer	2.94e-05	0.000463	CcSEcCtD
Nateglinide—Jaundice—Epirubicin—hematologic cancer	2.92e-05	0.00046	CcSEcCtD
Nateglinide—Vomiting—Thalidomide—hematologic cancer	2.92e-05	0.00046	CcSEcCtD
Nateglinide—Dizziness—Carmustine—hematologic cancer	2.91e-05	0.000459	CcSEcCtD
Nateglinide—Rash—Thalidomide—hematologic cancer	2.89e-05	0.000456	CcSEcCtD
Nateglinide—Dermatitis—Thalidomide—hematologic cancer	2.89e-05	0.000456	CcSEcCtD
Nateglinide—Upper respiratory tract infection—Doxorubicin—hematologic cancer	2.89e-05	0.000455	CcSEcCtD
Nateglinide—Dizziness—Alitretinoin—hematologic cancer	2.89e-05	0.000455	CcSEcCtD
Nateglinide—Diarrhoea—Vincristine—hematologic cancer	2.88e-05	0.000454	CcSEcCtD
Nateglinide—Sweating—Epirubicin—hematologic cancer	2.87e-05	0.000453	CcSEcCtD
Nateglinide—Asthenia—Gemcitabine—hematologic cancer	2.86e-05	0.000451	CcSEcCtD
Nateglinide—Dizziness—Ifosfamide—hematologic cancer	2.85e-05	0.00045	CcSEcCtD
Nateglinide—Hepatobiliary disease—Epirubicin—hematologic cancer	2.83e-05	0.000447	CcSEcCtD
Nateglinide—Pruritus—Gemcitabine—hematologic cancer	2.82e-05	0.000445	CcSEcCtD
Nateglinide—Nausea—Thiotepa—hematologic cancer	2.82e-05	0.000444	CcSEcCtD
Nateglinide—Diarrhoea—Irinotecan—hematologic cancer	2.8e-05	0.000442	CcSEcCtD
Nateglinide—Diarrhoea—Mitoxantrone—hematologic cancer	2.8e-05	0.000442	CcSEcCtD
Nateglinide—Vomiting—Carmustine—hematologic cancer	2.8e-05	0.000442	CcSEcCtD
Nateglinide—Gastrointestinal pain—Etoposide—hematologic cancer	2.79e-05	0.000439	CcSEcCtD
Nateglinide—Dizziness—Vincristine—hematologic cancer	2.78e-05	0.000439	CcSEcCtD
Nateglinide—Rash—Carmustine—hematologic cancer	2.78e-05	0.000438	CcSEcCtD
Nateglinide—Dermatitis—Carmustine—hematologic cancer	2.78e-05	0.000438	CcSEcCtD
Nateglinide—Vomiting—Alitretinoin—hematologic cancer	2.78e-05	0.000438	CcSEcCtD
Nateglinide—Rash—Alitretinoin—hematologic cancer	2.75e-05	0.000434	CcSEcCtD
Nateglinide—Dermatitis—Alitretinoin—hematologic cancer	2.75e-05	0.000433	CcSEcCtD
Nateglinide—Vomiting—Ifosfamide—hematologic cancer	2.74e-05	0.000432	CcSEcCtD
Nateglinide—Hypersensitivity—Cisplatin—hematologic cancer	2.74e-05	0.000432	CcSEcCtD
Nateglinide—Diarrhoea—Gemcitabine—hematologic cancer	2.73e-05	0.00043	CcSEcCtD
Nateglinide—Nausea—Thalidomide—hematologic cancer	2.72e-05	0.00043	CcSEcCtD
Nateglinide—Dyspepsia—Triamcinolone—hematologic cancer	2.72e-05	0.000429	CcSEcCtD
Nateglinide—Rash—Ifosfamide—hematologic cancer	2.72e-05	0.000429	CcSEcCtD
Nateglinide—Dermatitis—Ifosfamide—hematologic cancer	2.72e-05	0.000428	CcSEcCtD
Nateglinide—Erythema multiforme—Methotrexate—hematologic cancer	2.72e-05	0.000428	CcSEcCtD
Nateglinide—Neuropathy peripheral—Doxorubicin—hematologic cancer	2.72e-05	0.000428	CcSEcCtD
Nateglinide—Hyperhidrosis—Dexamethasone—hematologic cancer	2.71e-05	0.000427	CcSEcCtD
Nateglinide—Hyperhidrosis—Betamethasone—hematologic cancer	2.71e-05	0.000427	CcSEcCtD
Nateglinide—Dizziness—Irinotecan—hematologic cancer	2.71e-05	0.000427	CcSEcCtD
Nateglinide—Urticaria—Etoposide—hematologic cancer	2.71e-05	0.000427	CcSEcCtD
Nateglinide—Jaundice—Doxorubicin—hematologic cancer	2.7e-05	0.000426	CcSEcCtD
Nateglinide—Abdominal pain—Etoposide—hematologic cancer	2.69e-05	0.000425	CcSEcCtD
Nateglinide—Vomiting—Vincristine—hematologic cancer	2.67e-05	0.000422	CcSEcCtD
Nateglinide—Urticaria—Prednisolone—hematologic cancer	2.67e-05	0.000421	CcSEcCtD
Nateglinide—Asthenia—Cisplatin—hematologic cancer	2.67e-05	0.000421	CcSEcCtD
Nateglinide—Fatigue—Triamcinolone—hematologic cancer	2.66e-05	0.00042	CcSEcCtD
Nateglinide—Sweating—Doxorubicin—hematologic cancer	2.66e-05	0.000419	CcSEcCtD
Nateglinide—Rash—Vincristine—hematologic cancer	2.65e-05	0.000418	CcSEcCtD
Nateglinide—Dermatitis—Vincristine—hematologic cancer	2.65e-05	0.000418	CcSEcCtD
Nateglinide—Oedema peripheral—Epirubicin—hematologic cancer	2.65e-05	0.000418	CcSEcCtD
Nateglinide—Hepatobiliary disease—Doxorubicin—hematologic cancer	2.62e-05	0.000413	CcSEcCtD
Nateglinide—Nausea—Carmustine—hematologic cancer	2.62e-05	0.000413	CcSEcCtD
Nateglinide—Vomiting—Mitoxantrone—hematologic cancer	2.6e-05	0.000411	CcSEcCtD
Nateglinide—Vomiting—Irinotecan—hematologic cancer	2.6e-05	0.000411	CcSEcCtD
Nateglinide—Immune system disorder—Methotrexate—hematologic cancer	2.59e-05	0.000409	CcSEcCtD
Nateglinide—Nausea—Alitretinoin—hematologic cancer	2.59e-05	0.000409	CcSEcCtD
Nateglinide—Rash—Irinotecan—hematologic cancer	2.58e-05	0.000407	CcSEcCtD
Nateglinide—Rash—Mitoxantrone—hematologic cancer	2.58e-05	0.000407	CcSEcCtD
Nateglinide—Dermatitis—Mitoxantrone—hematologic cancer	2.58e-05	0.000407	CcSEcCtD
Nateglinide—Dermatitis—Irinotecan—hematologic cancer	2.58e-05	0.000407	CcSEcCtD
Nateglinide—Nausea—Ifosfamide—hematologic cancer	2.56e-05	0.000404	CcSEcCtD
Nateglinide—Diarrhoea—Cisplatin—hematologic cancer	2.54e-05	0.000401	CcSEcCtD
Nateglinide—Erythema multiforme—Epirubicin—hematologic cancer	2.54e-05	0.000401	CcSEcCtD
Nateglinide—Vomiting—Gemcitabine—hematologic cancer	2.54e-05	0.0004	CcSEcCtD
Nateglinide—Cilazapril—ABCB1—hematologic cancer	2.53e-05	0.192	CrCbGaD
Nateglinide—Lisinopril—ABCB1—hematologic cancer	2.53e-05	0.192	CrCbGaD
Nateglinide—Rash—Gemcitabine—hematologic cancer	2.52e-05	0.000397	CcSEcCtD
Nateglinide—Dermatitis—Gemcitabine—hematologic cancer	2.51e-05	0.000396	CcSEcCtD
Nateglinide—Hypersensitivity—Etoposide—hematologic cancer	2.51e-05	0.000396	CcSEcCtD
Nateglinide—Malnutrition—Methotrexate—hematologic cancer	2.5e-05	0.000394	CcSEcCtD
Nateglinide—Nausea—Vincristine—hematologic cancer	2.5e-05	0.000394	CcSEcCtD
Nateglinide—Hypersensitivity—Prednisolone—hematologic cancer	2.48e-05	0.00039	CcSEcCtD
Nateglinide—Dyspepsia—Dexamethasone—hematologic cancer	2.47e-05	0.000389	CcSEcCtD
Nateglinide—Dyspepsia—Betamethasone—hematologic cancer	2.47e-05	0.000389	CcSEcCtD
Nateglinide—Urticaria—Triamcinolone—hematologic cancer	2.45e-05	0.000387	CcSEcCtD
Nateglinide—Oedema peripheral—Doxorubicin—hematologic cancer	2.45e-05	0.000386	CcSEcCtD
Nateglinide—Asthenia—Etoposide—hematologic cancer	2.44e-05	0.000385	CcSEcCtD
Nateglinide—Nausea—Mitoxantrone—hematologic cancer	2.43e-05	0.000384	CcSEcCtD
Nateglinide—Nausea—Irinotecan—hematologic cancer	2.43e-05	0.000384	CcSEcCtD
Nateglinide—Immune system disorder—Epirubicin—hematologic cancer	2.43e-05	0.000383	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Dexamethasone—hematologic cancer	2.42e-05	0.000382	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Betamethasone—hematologic cancer	2.42e-05	0.000382	CcSEcCtD
Nateglinide—Back pain—Methotrexate—hematologic cancer	2.42e-05	0.000381	CcSEcCtD
Nateglinide—Fatigue—Dexamethasone—hematologic cancer	2.42e-05	0.000381	CcSEcCtD
Nateglinide—Fatigue—Betamethasone—hematologic cancer	2.42e-05	0.000381	CcSEcCtD
Nateglinide—Pruritus—Etoposide—hematologic cancer	2.41e-05	0.00038	CcSEcCtD
Nateglinide—Nausea—Gemcitabine—hematologic cancer	2.37e-05	0.000374	CcSEcCtD
Nateglinide—Vomiting—Cisplatin—hematologic cancer	2.36e-05	0.000373	CcSEcCtD
Nateglinide—Hyperhidrosis—Prednisone—hematologic cancer	2.36e-05	0.000372	CcSEcCtD
Nateglinide—Erythema multiforme—Doxorubicin—hematologic cancer	2.35e-05	0.000371	CcSEcCtD
Nateglinide—Rash—Cisplatin—hematologic cancer	2.34e-05	0.00037	CcSEcCtD
Nateglinide—Dermatitis—Cisplatin—hematologic cancer	2.34e-05	0.000369	CcSEcCtD
Nateglinide—Malnutrition—Epirubicin—hematologic cancer	2.34e-05	0.000369	CcSEcCtD
Nateglinide—Diarrhoea—Etoposide—hematologic cancer	2.33e-05	0.000368	CcSEcCtD
Nateglinide—Gastrointestinal pain—Dexamethasone—hematologic cancer	2.29e-05	0.000362	CcSEcCtD
Nateglinide—Gastrointestinal pain—Betamethasone—hematologic cancer	2.29e-05	0.000362	CcSEcCtD
Nateglinide—Hypersensitivity—Triamcinolone—hematologic cancer	2.28e-05	0.000359	CcSEcCtD
Nateglinide—Back pain—Epirubicin—hematologic cancer	2.26e-05	0.000357	CcSEcCtD
Nateglinide—Dizziness—Etoposide—hematologic cancer	2.25e-05	0.000355	CcSEcCtD
Nateglinide—Immune system disorder—Doxorubicin—hematologic cancer	2.25e-05	0.000354	CcSEcCtD
Nateglinide—Urticaria—Betamethasone—hematologic cancer	2.23e-05	0.000351	CcSEcCtD
Nateglinide—Urticaria—Dexamethasone—hematologic cancer	2.23e-05	0.000351	CcSEcCtD
Nateglinide—Dizziness—Prednisolone—hematologic cancer	2.22e-05	0.00035	CcSEcCtD
Nateglinide—Asthenia—Triamcinolone—hematologic cancer	2.22e-05	0.00035	CcSEcCtD
Nateglinide—Abdominal pain—Dexamethasone—hematologic cancer	2.22e-05	0.000349	CcSEcCtD
Nateglinide—Abdominal pain—Betamethasone—hematologic cancer	2.22e-05	0.000349	CcSEcCtD
Nateglinide—Nausea—Cisplatin—hematologic cancer	2.21e-05	0.000348	CcSEcCtD
Nateglinide—Pruritus—Triamcinolone—hematologic cancer	2.19e-05	0.000345	CcSEcCtD
Nateglinide—Cough—Methotrexate—hematologic cancer	2.18e-05	0.000344	CcSEcCtD
Nateglinide—Vomiting—Etoposide—hematologic cancer	2.17e-05	0.000342	CcSEcCtD
Nateglinide—Malnutrition—Doxorubicin—hematologic cancer	2.17e-05	0.000341	CcSEcCtD
Nateglinide—Dyspepsia—Prednisone—hematologic cancer	2.15e-05	0.000339	CcSEcCtD
Nateglinide—Rash—Etoposide—hematologic cancer	2.15e-05	0.000339	CcSEcCtD
Nateglinide—Dermatitis—Etoposide—hematologic cancer	2.15e-05	0.000338	CcSEcCtD
Nateglinide—Rash—Prednisolone—hematologic cancer	2.12e-05	0.000334	CcSEcCtD
Nateglinide—Dermatitis—Prednisolone—hematologic cancer	2.12e-05	0.000334	CcSEcCtD
Nateglinide—Fatigue—Prednisone—hematologic cancer	2.11e-05	0.000332	CcSEcCtD
Nateglinide—Back pain—Doxorubicin—hematologic cancer	2.09e-05	0.00033	CcSEcCtD
Nateglinide—Palpitations—Epirubicin—hematologic cancer	2.07e-05	0.000326	CcSEcCtD
Nateglinide—Dizziness—Triamcinolone—hematologic cancer	2.04e-05	0.000322	CcSEcCtD
Nateglinide—Cough—Epirubicin—hematologic cancer	2.04e-05	0.000322	CcSEcCtD
Nateglinide—Nausea—Etoposide—hematologic cancer	2.02e-05	0.000319	CcSEcCtD
Nateglinide—Asthenia—Betamethasone—hematologic cancer	2.01e-05	0.000317	CcSEcCtD
Nateglinide—Asthenia—Dexamethasone—hematologic cancer	2.01e-05	0.000317	CcSEcCtD
Nateglinide—Gastrointestinal pain—Prednisone—hematologic cancer	2e-05	0.000315	CcSEcCtD
Nateglinide—Nausea—Prednisolone—hematologic cancer	2e-05	0.000315	CcSEcCtD
Nateglinide—Pruritus—Dexamethasone—hematologic cancer	1.98e-05	0.000313	CcSEcCtD
Nateglinide—Pruritus—Betamethasone—hematologic cancer	1.98e-05	0.000313	CcSEcCtD
Nateglinide—Hyperhidrosis—Methotrexate—hematologic cancer	1.97e-05	0.000311	CcSEcCtD
Nateglinide—Vomiting—Triamcinolone—hematologic cancer	1.96e-05	0.00031	CcSEcCtD
Nateglinide—Rash—Triamcinolone—hematologic cancer	1.95e-05	0.000307	CcSEcCtD
Nateglinide—Dermatitis—Triamcinolone—hematologic cancer	1.95e-05	0.000307	CcSEcCtD
Nateglinide—Urticaria—Prednisone—hematologic cancer	1.94e-05	0.000306	CcSEcCtD
Nateglinide—Abdominal pain—Prednisone—hematologic cancer	1.93e-05	0.000304	CcSEcCtD
Nateglinide—Diarrhoea—Dexamethasone—hematologic cancer	1.92e-05	0.000302	CcSEcCtD
Nateglinide—Diarrhoea—Betamethasone—hematologic cancer	1.92e-05	0.000302	CcSEcCtD
Nateglinide—Palpitations—Doxorubicin—hematologic cancer	1.91e-05	0.000302	CcSEcCtD
Nateglinide—Cough—Doxorubicin—hematologic cancer	1.89e-05	0.000298	CcSEcCtD
Nateglinide—Enalapril—ABCB1—hematologic cancer	1.86e-05	0.141	CrCbGaD
Nateglinide—Dizziness—Dexamethasone—hematologic cancer	1.85e-05	0.000292	CcSEcCtD
Nateglinide—Dizziness—Betamethasone—hematologic cancer	1.85e-05	0.000292	CcSEcCtD
Nateglinide—Hyperhidrosis—Epirubicin—hematologic cancer	1.85e-05	0.000291	CcSEcCtD
Nateglinide—Nausea—Triamcinolone—hematologic cancer	1.84e-05	0.000289	CcSEcCtD
Nateglinide—Hypersensitivity—Prednisone—hematologic cancer	1.8e-05	0.000284	CcSEcCtD
Nateglinide—Dyspepsia—Methotrexate—hematologic cancer	1.8e-05	0.000283	CcSEcCtD
Nateglinide—Vomiting—Betamethasone—hematologic cancer	1.78e-05	0.000281	CcSEcCtD
Nateglinide—Vomiting—Dexamethasone—hematologic cancer	1.78e-05	0.000281	CcSEcCtD
Nateglinide—Rash—Betamethasone—hematologic cancer	1.77e-05	0.000279	CcSEcCtD
Nateglinide—Rash—Dexamethasone—hematologic cancer	1.77e-05	0.000279	CcSEcCtD
Nateglinide—Dermatitis—Dexamethasone—hematologic cancer	1.77e-05	0.000278	CcSEcCtD
Nateglinide—Dermatitis—Betamethasone—hematologic cancer	1.77e-05	0.000278	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Methotrexate—hematologic cancer	1.76e-05	0.000278	CcSEcCtD
Nateglinide—Fatigue—Methotrexate—hematologic cancer	1.76e-05	0.000277	CcSEcCtD
Nateglinide—Asthenia—Prednisone—hematologic cancer	1.75e-05	0.000276	CcSEcCtD
Nateglinide—Pruritus—Prednisone—hematologic cancer	1.73e-05	0.000272	CcSEcCtD
Nateglinide—Hyperhidrosis—Doxorubicin—hematologic cancer	1.71e-05	0.000269	CcSEcCtD
Nateglinide—Dyspepsia—Epirubicin—hematologic cancer	1.68e-05	0.000265	CcSEcCtD
Nateglinide—Diarrhoea—Prednisone—hematologic cancer	1.67e-05	0.000263	CcSEcCtD
Nateglinide—Gastrointestinal pain—Methotrexate—hematologic cancer	1.67e-05	0.000263	CcSEcCtD
Nateglinide—Nausea—Betamethasone—hematologic cancer	1.67e-05	0.000263	CcSEcCtD
Nateglinide—Nausea—Dexamethasone—hematologic cancer	1.67e-05	0.000263	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Epirubicin—hematologic cancer	1.65e-05	0.00026	CcSEcCtD
Nateglinide—Fatigue—Epirubicin—hematologic cancer	1.65e-05	0.00026	CcSEcCtD
Nateglinide—Urticaria—Methotrexate—hematologic cancer	1.62e-05	0.000256	CcSEcCtD
Nateglinide—Dizziness—Prednisone—hematologic cancer	1.61e-05	0.000255	CcSEcCtD
Nateglinide—Abdominal pain—Methotrexate—hematologic cancer	1.61e-05	0.000254	CcSEcCtD
Nateglinide—Gastrointestinal pain—Epirubicin—hematologic cancer	1.56e-05	0.000246	CcSEcCtD
Nateglinide—Dyspepsia—Doxorubicin—hematologic cancer	1.56e-05	0.000245	CcSEcCtD
Nateglinide—Vomiting—Prednisone—hematologic cancer	1.55e-05	0.000245	CcSEcCtD
Nateglinide—Rash—Prednisone—hematologic cancer	1.54e-05	0.000243	CcSEcCtD
Nateglinide—Dermatitis—Prednisone—hematologic cancer	1.54e-05	0.000243	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Doxorubicin—hematologic cancer	1.53e-05	0.000241	CcSEcCtD
Nateglinide—Fatigue—Doxorubicin—hematologic cancer	1.52e-05	0.00024	CcSEcCtD
Nateglinide—Urticaria—Epirubicin—hematologic cancer	1.52e-05	0.000239	CcSEcCtD
Nateglinide—Abdominal pain—Epirubicin—hematologic cancer	1.51e-05	0.000238	CcSEcCtD
Nateglinide—Hypersensitivity—Methotrexate—hematologic cancer	1.5e-05	0.000237	CcSEcCtD
Nateglinide—Asthenia—Methotrexate—hematologic cancer	1.46e-05	0.000231	CcSEcCtD
Nateglinide—Nausea—Prednisone—hematologic cancer	1.45e-05	0.000229	CcSEcCtD
Nateglinide—Gastrointestinal pain—Doxorubicin—hematologic cancer	1.44e-05	0.000228	CcSEcCtD
Nateglinide—Pruritus—Methotrexate—hematologic cancer	1.44e-05	0.000228	CcSEcCtD
Nateglinide—Hypersensitivity—Epirubicin—hematologic cancer	1.41e-05	0.000222	CcSEcCtD
Nateglinide—Urticaria—Doxorubicin—hematologic cancer	1.4e-05	0.000221	CcSEcCtD
Nateglinide—Abdominal pain—Doxorubicin—hematologic cancer	1.4e-05	0.00022	CcSEcCtD
Nateglinide—Diarrhoea—Methotrexate—hematologic cancer	1.4e-05	0.00022	CcSEcCtD
Nateglinide—Asthenia—Epirubicin—hematologic cancer	1.37e-05	0.000216	CcSEcCtD
Nateglinide—Pruritus—Epirubicin—hematologic cancer	1.35e-05	0.000213	CcSEcCtD
Nateglinide—Dizziness—Methotrexate—hematologic cancer	1.35e-05	0.000213	CcSEcCtD
Nateglinide—Diarrhoea—Epirubicin—hematologic cancer	1.31e-05	0.000206	CcSEcCtD
Nateglinide—Hypersensitivity—Doxorubicin—hematologic cancer	1.3e-05	0.000205	CcSEcCtD
Nateglinide—Vomiting—Methotrexate—hematologic cancer	1.3e-05	0.000205	CcSEcCtD
Nateglinide—Rash—Methotrexate—hematologic cancer	1.29e-05	0.000203	CcSEcCtD
Nateglinide—Dermatitis—Methotrexate—hematologic cancer	1.29e-05	0.000203	CcSEcCtD
Nateglinide—Asthenia—Doxorubicin—hematologic cancer	1.27e-05	0.0002	CcSEcCtD
Nateglinide—Dizziness—Epirubicin—hematologic cancer	1.26e-05	0.000199	CcSEcCtD
Nateglinide—Pruritus—Doxorubicin—hematologic cancer	1.25e-05	0.000197	CcSEcCtD
Nateglinide—Vomiting—Epirubicin—hematologic cancer	1.21e-05	0.000191	CcSEcCtD
Nateglinide—Nausea—Methotrexate—hematologic cancer	1.21e-05	0.000191	CcSEcCtD
Nateglinide—Diarrhoea—Doxorubicin—hematologic cancer	1.21e-05	0.000191	CcSEcCtD
Nateglinide—Rash—Epirubicin—hematologic cancer	1.2e-05	0.00019	CcSEcCtD
Nateglinide—Dermatitis—Epirubicin—hematologic cancer	1.2e-05	0.00019	CcSEcCtD
Nateglinide—Dizziness—Doxorubicin—hematologic cancer	1.17e-05	0.000184	CcSEcCtD
Nateglinide—Nausea—Epirubicin—hematologic cancer	1.13e-05	0.000179	CcSEcCtD
Nateglinide—Vomiting—Doxorubicin—hematologic cancer	1.12e-05	0.000177	CcSEcCtD
Nateglinide—Rash—Doxorubicin—hematologic cancer	1.11e-05	0.000176	CcSEcCtD
Nateglinide—Dermatitis—Doxorubicin—hematologic cancer	1.11e-05	0.000176	CcSEcCtD
Nateglinide—Nausea—Doxorubicin—hematologic cancer	1.05e-05	0.000165	CcSEcCtD
Nateglinide—CYP2C9—Metabolism—SPHK1—hematologic cancer	1.83e-06	5.23e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—ENO2—hematologic cancer	1.82e-06	5.22e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—PIK3CD—hematologic cancer	1.81e-06	5.19e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—NCOR1—hematologic cancer	1.81e-06	5.18e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—GSTM1—hematologic cancer	1.81e-06	5.18e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—ABCB1—hematologic cancer	1.81e-06	5.17e-05	CbGpPWpGaD
Nateglinide—PPARG—Developmental Biology—AKT1—hematologic cancer	1.78e-06	5.11e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—UGT1A1—hematologic cancer	1.77e-06	5.07e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—GSTT1—hematologic cancer	1.77e-06	5.06e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—UGT1A1—hematologic cancer	1.75e-06	5.03e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—GSTM1—hematologic cancer	1.75e-06	5.02e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—NCOR1—hematologic cancer	1.75e-06	5.02e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—MTAP—hematologic cancer	1.75e-06	5e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	1.74e-06	4.99e-05	CbGpPWpGaD
Nateglinide—ABCC4—Hemostasis—AKT1—hematologic cancer	1.74e-06	4.98e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—SDC1—hematologic cancer	1.73e-06	4.95e-05	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—CREBBP—hematologic cancer	1.72e-06	4.94e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—SLC22A1—hematologic cancer	1.72e-06	4.93e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—CRABP1—hematologic cancer	1.72e-06	4.93e-05	CbGpPWpGaD
Nateglinide—ABCC8—Metabolism—PTEN—hematologic cancer	1.72e-06	4.92e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—PIK3R1—hematologic cancer	1.71e-06	4.9e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—SLC22A1—hematologic cancer	1.71e-06	4.89e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—CRABP1—hematologic cancer	1.71e-06	4.89e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—CD44—hematologic cancer	1.71e-06	4.89e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—NQO1—hematologic cancer	1.71e-06	4.89e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—ALOX5—hematologic cancer	1.68e-06	4.81e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.67e-06	4.8e-05	CbGpPWpGaD
Nateglinide—KCNJ11—Metabolism—PTEN—hematologic cancer	1.66e-06	4.77e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—JAK2—hematologic cancer	1.66e-06	4.77e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—ALOX5—hematologic cancer	1.66e-06	4.76e-05	CbGpPWpGaD
Nateglinide—ALB—Transmembrane transport of small molecules—CREBBP—hematologic cancer	1.65e-06	4.74e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	1.65e-06	4.73e-05	CbGpPWpGaD
Nateglinide—SLC16A1—Metabolism—PTEN—hematologic cancer	1.64e-06	4.7e-05	CbGpPWpGaD
Nateglinide—ABCC8—Metabolism—EP300—hematologic cancer	1.64e-06	4.69e-05	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—PIK3CD—hematologic cancer	1.63e-06	4.68e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—NUP98—hematologic cancer	1.62e-06	4.65e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—CYCS—hematologic cancer	1.61e-06	4.62e-05	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—ALB—hematologic cancer	1.61e-06	4.62e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—NUP98—hematologic cancer	1.61e-06	4.61e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—HSP90AA1—hematologic cancer	1.6e-06	4.59e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—MTHFR—hematologic cancer	1.6e-06	4.58e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—PIK3CG—hematologic cancer	1.6e-06	4.57e-05	CbGpPWpGaD
Nateglinide—KCNJ11—Metabolism—EP300—hematologic cancer	1.59e-06	4.55e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—PIK3CB—hematologic cancer	1.58e-06	4.53e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—NCOA3—hematologic cancer	1.58e-06	4.52e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—ADCY7—hematologic cancer	1.58e-06	4.52e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—NUP214—hematologic cancer	1.57e-06	4.49e-05	CbGpPWpGaD
Nateglinide—SLC16A1—Metabolism—EP300—hematologic cancer	1.56e-06	4.48e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—ADCY7—hematologic cancer	1.56e-06	4.48e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—NCOA3—hematologic cancer	1.56e-06	4.48e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	1.56e-06	4.46e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—FHL2—hematologic cancer	1.56e-06	4.46e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—NUP214—hematologic cancer	1.55e-06	4.45e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—MTHFR—hematologic cancer	1.55e-06	4.44e-05	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—PIK3R1—hematologic cancer	1.54e-06	4.42e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	1.54e-06	4.4e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—ABCG2—hematologic cancer	1.53e-06	4.4e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—MTR—hematologic cancer	1.53e-06	4.4e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—AGRN—hematologic cancer	1.53e-06	4.37e-05	CbGpPWpGaD
Nateglinide—ALB—Platelet activation, signaling and aggregation—AKT1—hematologic cancer	1.53e-06	4.37e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—MTR—hematologic cancer	1.52e-06	4.36e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—ABCG2—hematologic cancer	1.52e-06	4.36e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—ENO2—hematologic cancer	1.5e-06	4.31e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—ENO2—hematologic cancer	1.49e-06	4.27e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—CREBBP—hematologic cancer	1.48e-06	4.24e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—NQO1—hematologic cancer	1.47e-06	4.21e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—CD44—hematologic cancer	1.47e-06	4.21e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—GSTT1—hematologic cancer	1.46e-06	4.18e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—IL2—hematologic cancer	1.45e-06	4.16e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—IDH2—hematologic cancer	1.45e-06	4.15e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—HMMR—hematologic cancer	1.45e-06	4.15e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—GSTT1—hematologic cancer	1.45e-06	4.14e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	1.44e-06	4.12e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—SDC1—hematologic cancer	1.43e-06	4.09e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	1.42e-06	4.08e-05	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—PIK3CB—hematologic cancer	1.42e-06	4.08e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—GSTP1—hematologic cancer	1.42e-06	4.08e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—SDC1—hematologic cancer	1.41e-06	4.05e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—PIK3CD—hematologic cancer	1.4e-06	4.02e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—CYCS—hematologic cancer	1.39e-06	3.98e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—ALB—hematologic cancer	1.39e-06	3.97e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—HSP90AA1—hematologic cancer	1.38e-06	3.96e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.37e-06	3.91e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—ARNTL—hematologic cancer	1.36e-06	3.9e-05	CbGpPWpGaD
Nateglinide—PPARG—Gene Expression—MAPK3—hematologic cancer	1.35e-06	3.87e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	1.35e-06	3.87e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—ABCB1—hematologic cancer	1.35e-06	3.86e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—PIK3CG—hematologic cancer	1.34e-06	3.85e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	1.33e-06	3.82e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—PIK3R1—hematologic cancer	1.33e-06	3.8e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—CA9—hematologic cancer	1.32e-06	3.79e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—ACP5—hematologic cancer	1.32e-06	3.79e-05	CbGpPWpGaD
Nateglinide—PPARG—Gene Expression—MYC—hematologic cancer	1.31e-06	3.77e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—GSTM1—hematologic cancer	1.31e-06	3.75e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—NCOR1—hematologic cancer	1.31e-06	3.75e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—NCOR2—hematologic cancer	1.31e-06	3.74e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—EP300—hematologic cancer	1.3e-06	3.73e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—PIK3CG—hematologic cancer	1.3e-06	3.73e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	1.28e-06	3.65e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—SRC—hematologic cancer	1.27e-06	3.63e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—CREBBP—hematologic cancer	1.25e-06	3.57e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—IDH1—hematologic cancer	1.24e-06	3.57e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.24e-06	3.56e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—VEGFA—hematologic cancer	1.23e-06	3.53e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—ABCC3—hematologic cancer	1.23e-06	3.53e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—TXN—hematologic cancer	1.23e-06	3.53e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—GSTO1—hematologic cancer	1.23e-06	3.53e-05	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—PTEN—hematologic cancer	1.23e-06	3.52e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—GSTP1—hematologic cancer	1.23e-06	3.51e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—PIK3CB—hematologic cancer	1.22e-06	3.51e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—NRAS—hematologic cancer	1.22e-06	3.49e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—NQO1—hematologic cancer	1.21e-06	3.47e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—CD44—hematologic cancer	1.21e-06	3.47e-05	CbGpPWpGaD
Nateglinide—ABCC8—Metabolism—PIK3CA—hematologic cancer	1.21e-06	3.47e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—CREBBP—hematologic cancer	1.21e-06	3.46e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—SPHK1—hematologic cancer	1.2e-06	3.45e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—NQO1—hematologic cancer	1.2e-06	3.44e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—CD44—hematologic cancer	1.2e-06	3.44e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.19e-06	3.4e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—PIK3CD—hematologic cancer	1.18e-06	3.38e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	1.18e-06	3.37e-05	CbGpPWpGaD
Nateglinide—KCNJ11—Metabolism—PIK3CA—hematologic cancer	1.17e-06	3.36e-05	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—EP300—hematologic cancer	1.17e-06	3.36e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—MAPK3—hematologic cancer	1.17e-06	3.34e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—ALB—hematologic cancer	1.17e-06	3.34e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—ABCB1—hematologic cancer	1.16e-06	3.32e-05	CbGpPWpGaD
Nateglinide—SLC16A1—Metabolism—PIK3CA—hematologic cancer	1.16e-06	3.32e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—UGT1A1—hematologic cancer	1.16e-06	3.31e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—MTHFR—hematologic cancer	1.16e-06	3.31e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—CYCS—hematologic cancer	1.15e-06	3.29e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—PIK3CD—hematologic cancer	1.14e-06	3.28e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	1.14e-06	3.27e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—CYCS—hematologic cancer	1.14e-06	3.26e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—TGFB1—hematologic cancer	1.13e-06	3.24e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—HSP90AA1—hematologic cancer	1.13e-06	3.24e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—ALB—hematologic cancer	1.13e-06	3.24e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—NCOR1—hematologic cancer	1.13e-06	3.23e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—GSTM1—hematologic cancer	1.13e-06	3.23e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—SLC22A1—hematologic cancer	1.13e-06	3.22e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—CRABP1—hematologic cancer	1.13e-06	3.22e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—PIK3R1—hematologic cancer	1.11e-06	3.19e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—ALOX5—hematologic cancer	1.1e-06	3.14e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—PIK3R1—hematologic cancer	1.08e-06	3.1e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—NUP98—hematologic cancer	1.06e-06	3.04e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—PTEN—hematologic cancer	1.06e-06	3.03e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—KRAS—hematologic cancer	1.05e-06	3e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—ADCY7—hematologic cancer	1.03e-06	2.95e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—NCOA3—hematologic cancer	1.03e-06	2.95e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—PIK3CB—hematologic cancer	1.03e-06	2.95e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—NUP214—hematologic cancer	1.02e-06	2.93e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.02e-06	2.91e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—GSTP1—hematologic cancer	1.01e-06	2.9e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—EP300—hematologic cancer	1.01e-06	2.89e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—MTR—hematologic cancer	1e-06	2.87e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—ABCG2—hematologic cancer	1e-06	2.87e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—GSTP1—hematologic cancer	1e-06	2.87e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—PIK3CB—hematologic cancer	9.97e-07	2.86e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—MTHFR—hematologic cancer	9.95e-07	2.85e-05	CbGpPWpGaD
Nateglinide—ABCC8—Metabolism—AKT1—hematologic cancer	9.89e-07	2.83e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—ENO2—hematologic cancer	9.84e-07	2.82e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—PIK3CG—hematologic cancer	9.71e-07	2.78e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	9.7e-07	2.78e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—PIK3CA—hematologic cancer	9.63e-07	2.76e-05	CbGpPWpGaD
Nateglinide—KCNJ11—Metabolism—AKT1—hematologic cancer	9.59e-07	2.75e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—ABCB1—hematologic cancer	9.58e-07	2.74e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—GSTT1—hematologic cancer	9.54e-07	2.73e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—ABCB1—hematologic cancer	9.49e-07	2.72e-05	CbGpPWpGaD
Nateglinide—SLC16A1—Metabolism—AKT1—hematologic cancer	9.46e-07	2.71e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—SDC1—hematologic cancer	9.33e-07	2.67e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—TP53—hematologic cancer	9.32e-07	2.67e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—NCOR1—hematologic cancer	9.3e-07	2.66e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—GSTM1—hematologic cancer	9.3e-07	2.66e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—GSTM1—hematologic cancer	9.22e-07	2.64e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—NCOR1—hematologic cancer	9.22e-07	2.64e-05	CbGpPWpGaD
Nateglinide—PPARG—Gene Expression—AKT1—hematologic cancer	9.12e-07	2.61e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—CREBBP—hematologic cancer	9e-07	2.58e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—HRAS—hematologic cancer	8.91e-07	2.55e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—PTEN—hematologic cancer	8.89e-07	2.55e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	8.77e-07	2.51e-05	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—PIK3CA—hematologic cancer	8.68e-07	2.49e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—PTEN—hematologic cancer	8.62e-07	2.47e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—PIK3CD—hematologic cancer	8.53e-07	2.44e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—EP300—hematologic cancer	8.48e-07	2.43e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—ALB—hematologic cancer	8.42e-07	2.41e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—PIK3CG—hematologic cancer	8.36e-07	2.39e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—EP300—hematologic cancer	8.22e-07	2.35e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—MTHFR—hematologic cancer	8.22e-07	2.35e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—MTHFR—hematologic cancer	8.14e-07	2.33e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—PIK3R1—hematologic cancer	8.06e-07	2.31e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—CD44—hematologic cancer	7.93e-07	2.27e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—NQO1—hematologic cancer	7.93e-07	2.27e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—AKT1—hematologic cancer	7.87e-07	2.25e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—CREBBP—hematologic cancer	7.75e-07	2.22e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—CYCS—hematologic cancer	7.5e-07	2.15e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—PIK3CA—hematologic cancer	7.46e-07	2.14e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	7.46e-07	2.14e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—PIK3CB—hematologic cancer	7.44e-07	2.13e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—PIK3CD—hematologic cancer	7.35e-07	2.11e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	7.18e-07	2.06e-05	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—AKT1—hematologic cancer	7.09e-07	2.03e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—PIK3R1—hematologic cancer	6.94e-07	1.99e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PIK3CG—hematologic cancer	6.9e-07	1.98e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PIK3CG—hematologic cancer	6.84e-07	1.96e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—GSTP1—hematologic cancer	6.61e-07	1.89e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—PTEN—hematologic cancer	6.43e-07	1.84e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—PIK3CB—hematologic cancer	6.41e-07	1.84e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—CREBBP—hematologic cancer	6.4e-07	1.83e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—CREBBP—hematologic cancer	6.34e-07	1.82e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—PIK3CA—hematologic cancer	6.27e-07	1.8e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—ABCB1—hematologic cancer	6.26e-07	1.79e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—EP300—hematologic cancer	6.13e-07	1.76e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—AKT1—hematologic cancer	6.09e-07	1.75e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—PIK3CA—hematologic cancer	6.08e-07	1.74e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—NCOR1—hematologic cancer	6.08e-07	1.74e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—GSTM1—hematologic cancer	6.08e-07	1.74e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PIK3CD—hematologic cancer	6.07e-07	1.74e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PIK3CD—hematologic cancer	6.02e-07	1.72e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—ALB—hematologic cancer	5.99e-07	1.72e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—ALB—hematologic cancer	5.94e-07	1.7e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PIK3R1—hematologic cancer	5.73e-07	1.64e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PIK3R1—hematologic cancer	5.68e-07	1.63e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—PTEN—hematologic cancer	5.54e-07	1.59e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—MTHFR—hematologic cancer	5.37e-07	1.54e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PIK3CB—hematologic cancer	5.29e-07	1.52e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—EP300—hematologic cancer	5.28e-07	1.51e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PIK3CB—hematologic cancer	5.24e-07	1.5e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—AKT1—hematologic cancer	5.12e-07	1.47e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—AKT1—hematologic cancer	4.97e-07	1.42e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PTEN—hematologic cancer	4.57e-07	1.31e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—PIK3CA—hematologic cancer	4.53e-07	1.3e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PTEN—hematologic cancer	4.53e-07	1.3e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PIK3CG—hematologic cancer	4.51e-07	1.29e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—EP300—hematologic cancer	4.36e-07	1.25e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—EP300—hematologic cancer	4.32e-07	1.24e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—CREBBP—hematologic cancer	4.18e-07	1.2e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PIK3CD—hematologic cancer	3.97e-07	1.14e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—ALB—hematologic cancer	3.92e-07	1.12e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—PIK3CA—hematologic cancer	3.91e-07	1.12e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PIK3R1—hematologic cancer	3.75e-07	1.07e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—AKT1—hematologic cancer	3.7e-07	1.06e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PIK3CB—hematologic cancer	3.46e-07	9.91e-06	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PIK3CA—hematologic cancer	3.22e-07	9.24e-06	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PIK3CA—hematologic cancer	3.2e-07	9.16e-06	CbGpPWpGaD
Nateglinide—ALB—Metabolism—AKT1—hematologic cancer	3.19e-07	9.14e-06	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PTEN—hematologic cancer	2.99e-07	8.56e-06	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—EP300—hematologic cancer	2.85e-07	8.16e-06	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—AKT1—hematologic cancer	2.63e-07	7.55e-06	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—AKT1—hematologic cancer	2.61e-07	7.48e-06	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PIK3CA—hematologic cancer	2.11e-07	6.04e-06	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—AKT1—hematologic cancer	1.72e-07	4.93e-06	CbGpPWpGaD
